Figure 1 Gel electrophoresis of C3435T polymorphism from tissue samples. Left: The last lane from the right is 50 bp DNA ladder. Samples in lanes 1, 3 and 5 represent the PCR products MK 8931 and samples in lanes 2, 4 and 6, are the digest products of each

sample, respectively. Sample in lane 2 is the mutant homozygous uncut TT genotype (197 bp). Sample in lane 4 represents the wild type cut CC genotype (158 bp and 39 bp). Sample in lane 6 represents heterozygous CT genotype (197 bp, 158 bp and 39 bp). Right: Gel electrophoresis of C3435T polymorphism from blood samples. The first lane from the left is 50 bp DNA ladder. Samples in lanes 1, 3 and 5 represent the PCR products and samples in lanes 2, 4 and 6, are the digest products of each sample, respectively. Sample in lane 2 is the mutant homozygous uncut TT genotype (197 bp). Sample in lane 4 represents the wild type cut CC genotype (158 bp and 39 bp). Sample in lane 6 represents heterozygous CT genotype (197 bp, 158 bp and 39 bp). Results in Table 2 revealed that both C and T alleles are common in the studied population with approximately equal distribution. However, the patient group showed significantly (P value < 0.05) higher frequencies of both mutant T allele (65%) and TT homozygous mutant genotype

(41%) compared to the control group. This indicates that the T allele in the C3435T polymorphism is associated with and HL occurrence. Table 2 Genotype and allele frequencies of C3435T polymorphism among HL patients and controls Genotypes & Alleles HL patients (130) N (%) Controls (120) N (%) P-value CC 15 (11.5) 37 (30.8)   CT 62 (47.7) 48 (40.0) 0.001 TT 53 (40.8) 35 (29.2)   Allele C 92 (35.4) 122 (50.8) 0.000 Captisol solubility dmso Allele T 168 (64.6) 118 (49.2)   No significant association between the C3435T genotypes (CC, CT and TT) and alleles (C and T) with patient’s baseline characteristics including

patient’s age, gender, specimen histology, stage of the disease and presence or absence of B-symptoms (Table 3 and 4), P value > 0.05. Table 3 Characteristics of patients according to C3435T genotypes Characteristics CC genotype N (%) CT genotype N (%) TT genotype N (%) P-value Age at diagnosis         < 30 (n = 62) 7 (46.7) 28 (45.2) 27 (50.9) 0.823 ≥ Interleukin-3 receptor 30 (n = 68) 8 (53.3) 34 (54.8) 26 (49.1)   Gender         Males (n = 71) 7 (46.7) 29 (46.8) 35 (66) 0.095 Females (n = 59) 8 (53.3) 33 (53.2) 18 (44)   Histology         NSa (n = 62) 9 (64.3) 32 (72.7) 21 (60) 0.481 MCb (n = 31) 5 (35.7) 12 (27.3) 14 (40)   Stage         Early stages (I &II) (n = 61) 7 (50) 30 (58) 24 (53.3) 0.842 Advanced stages (III & IV) (n = 50) 7 (50) 22 (42) 21 (46.7)   Presence of B-symptoms         Yes (n = 73) 9 (60) 36 (64.3) 28 (60.9) 0.920 No (n = 44) 6 (40) 20 (35.7) 18 (39.1)   aNodular sclerosis; bMixed cellularity. Table 4 Characteristics of patients according to C3435T alleles Characteristics C allele N (%) T allele N (%) Total P-value Age at diagnosis         < 30 42 (45.7) 82 (48.